Key Points
- CEO Matthew Kapusta sold 41,671 uniQure shares at $50 each, worth about $2.08 million, in a pre-arranged Rule 10b5-1 transaction. After the sale, he still directly held 521,795 shares, cutting his position by 7.4%.
- uniQure shares were trading around $44.39 and were down 4.1% in the session. The stock has ranged from a 12-month low of $8.73 to a high of $71.50, with a market cap of about $2.8 billion.
- Analysts remain generally positive on the biotech name, with 12 Buy ratings and a consensus Moderate Buy rating. The average price target is $58.92, while Cantor Fitzgerald recently raised its target to $61 and upgraded the stock to overweight.
uniQure N.V. (NASDAQ:QURE - Get Free Report) Director Jack Kaye sold 5,295 shares of the business's stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $42.57, for a total value of $225,408.15. Following the transaction, the director directly owned 25,996 shares of the company's stock, valued at $1,106,649.72. The trade was a 16.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jack Kaye also recently made the following trade(s):
- On Thursday, June 11th, Jack Kaye sold 1,993 shares of uniQure stock. The stock was sold at an average price of $27.06, for a total transaction of $53,930.58.
- On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The stock was sold at an average price of $30.01, for a total transaction of $79,376.45.
uniQure Stock Performance
NASDAQ:QURE opened at $44.39 on Tuesday. The business's fifty day moving average price is $25.30 and its 200 day moving average price is $22.30. The firm has a market capitalization of $2.80 billion, a PE ratio of -12.76 and a beta of 0.98. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.
uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts' consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. On average, sell-side analysts anticipate that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.
More uniQure News
Here are the key news stories impacting uniQure this week:
- Positive Sentiment: uniQure reported initial AMT-260 data in temporal lobe epilepsy showing meaningful seizure reductions in early patients, with no treatment-related serious adverse events, which supports the company’s gene-therapy pipeline. Article Title
- Positive Sentiment: Early trial updates also highlighted seizure reductions of 79% to 100% in three patients, reinforcing investor optimism around AMT-260’s potential. Article Title
- Neutral Sentiment: The company also announced preliminary data from the first cohort in its Phase I/IIa AMT-260 clinical trial, a routine but important catalyst for a development-stage biotech. Article Title
- Negative Sentiment: uniQure announced a $150 million underwritten public offering, with an additional $22.5 million greenshoe option, which could dilute existing shareholders even if it strengthens the balance sheet. Article Title
- Negative Sentiment: Recent insider selling by the CEO and two directors may also weigh on sentiment, even though the transactions were made under pre-arranged 10b5-1 plans. Article Title
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on QURE shares. TD Cowen restated a "buy" rating on shares of uniQure in a research report on Tuesday, March 3rd. Mizuho upgraded uniQure from a "neutral" rating to an "outperform" rating and boosted their target price for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. Chardan Capital upped their price target on shares of uniQure from $31.00 to $37.00 and gave the stock a "buy" rating in a research note on Thursday, April 30th. Barclays upgraded uniQure from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $25.00 to $65.00 in a report on Thursday, June 18th. Finally, Royal Bank Of Canada raised their target price on shares of uniQure from $35.00 to $65.00 and gave the company an "outperform" rating in a report on Thursday. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, uniQure currently has a consensus rating of "Moderate Buy" and an average target price of $58.92.
Read Our Latest Research Report on uniQure
Hedge Funds Weigh In On uniQure
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Woodline Partners LP increased its holdings in shares of uniQure by 25.0% during the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company's stock worth $1,864,000 after buying an additional 35,175 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of uniQure during the second quarter valued at approximately $497,000. Marshall Wace LLP increased its stake in uniQure by 276.5% during the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company's stock worth $3,108,000 after buying an additional 163,749 shares during the period. California State Teachers Retirement System purchased a new stake in shares of uniQure during the second quarter worth about $540,000. Finally, Ameriprise Financial Inc. increased its holdings in uniQure by 38.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company's stock worth $10,622,000 after purchasing an additional 212,218 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.
uniQure Company Profile
(
Get Free Report)
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
